Prognostic value of KRAS in terms of efficacy and safety of bevacizumab as neoadjuvant or conversion treatment in patients with colorectal liver metastasis.
Pilar Garcia Alfonso
No relevant relationships to disclose
Andrés Jesús Muñoz Martin
No relevant relationships to disclose
Sonsoles Alvarez
No relevant relationships to disclose
M. Carmen Riesco
No relevant relationships to disclose
Montse Blanco Codeisido
No relevant relationships to disclose
Ana Belen Ruperez Blanco
No relevant relationships to disclose
Sara Custodio Cabello
No relevant relationships to disclose
Gonzalo Tapia
No relevant relationships to disclose
Rebeca Mondejar Solís
No relevant relationships to disclose
Miguel Martin
No relevant relationships to disclose